Given the high expression of CCR4 in a variety of T-cell malignancies, especially MF and SS, which promote the migration of malignant T cells into the skin and are closely associated with disease progression, CCR4 has emerged as a potential therapeutic target [70]. Here, CCR4 is linked to synovial sarcoma.